methylone
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2021 (NCT05488171)
Timeline
Indications
Mechanism of action
- Serotonin 2a (5-HT2a) receptorACTIVATOR
HTR2A activator
Chemistry & pharmacology
Loading structure…
SMILES
CNC(C)C(=O)c1ccc2c(c1)OCO2- Mol. weight
- 207.23 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3604010 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06215261 | Phase 2 | Apr 4, 2024 | Transcend Therapeutics |
| NCT06303648 | Phase 1 | Mar 20, 2024 | Transcend Therapeutics |
| NCT06237426 | Phase 2 | Mar 6, 2024 | Transcend Therapeutics |
| NCT05741710 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2023 | Transcend Therapeutics |
| NCT05488171 | Phase 1 | Dec 1, 2021 | Badalona Hospital Germans Trias i Pujol, Istituto Superiore di Sanità |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Transcend Therapeutics | For profit | 4 | 4 | 2 | 2023 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Istituto Superiore di Sanità | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1